[New aspects in the treatment of bronchial asthma and chronic obstructive lung diseases].
The expansion of our knowledge regarding the pathogenesis of asthma has now made clear that it is an inflammatory disease. Although the treatment of bronchospasm associated with asthma is essential, it is important to consider the inflammatory aspect of the disease. The first therapeutic approach is to control environmental hazards (allergen, air pollution, tobacco smoke). It should always be remembered that patient education is of critical importance. Patients with only occasional asthma symptoms (2-4 times a week) should receive inhaled short-acting beta-2 agonists as needed. Treatment with inhaled corticosteroids is instituted in all asthmatics except the mildest cases. Long-acting beta-2 agonists are an additional therapy for patients with unsatisfactory symptom control despite an optimal dose of inhaled steroids, particularly when there are nocturnal symptoms. Chronic obstructive pulmonary disease is defined as a disease state characterized by the presence of airflow obstruction due to chronic bronchitis or emphysema. Although the airflow obstruction is generally progressive, comprehensive therapeutic management benefits all patients including those with severe disease: stopping smoking, vaccination against influenza and pneumococcus, pharmacologic therapy. The judicious use of bronchodilators increases airflow and reduces dyspnea. Ipratropium and beta-2 agonists are equally efficacious and may work synergistically. The use of corticosteroids is controversial. Thus a closely monitored steroid trial of therapy should be considered in patients who have continuing symptoms or severe airflow limitation despite maximal therapy with other agents. Broad spectrum antibiotics are beneficial in severe exacerbations.